Drug Target Review is the essential resource for researchers and scientific leaders in drug discovery and early-phase therapeutic development. We ensure that the pharmaceutical and life science ...

Driven by a passion for innovation and inclusivity, Dr Catherine Pickering, CEO of iOnctura, is on a mission to transform cancer treatment while championing diversity within the biotech industry. In ...

Watch this webinar as we investigate how challenges in AI-driven drug discovery can be overcome. In this webinar, esteemed experts will explore strategies to improve data collection, integration and ...

Driven by a passion for innovation and inclusivity, Dr Catherine Pickering, CEO of iOnctura, is on a mission to transform cancer treatment while championing diversity within the biotech industry.

We had the privilege of talking to Veerle d’Haenens, General Manager, Global Therapy Innovations at Terumo Blood and Cell Technologies. Her successful career has been driven by her creativity, ...

Researchers have uncovered a how INPP4B, alongside PIKfyve and TRPML-1, drives pancreatic cancer metastasis. Researchers at the University of Toronto, Toronto Metropolitan University and the Princess ...

New collaboration focuses on transforming academic research into innovative therapies for urgent medical conditions, including cancer and heart disease. The University of Southern California (USC) has ...

Listen to this episode to discover how microbiomics is being leveraged to translate gut microbiome findings into new therapeutic options.

Renowned immunologist Dr Yang Liu shares his insights into the preclinical studies behind the development of drug candidates targeting the CD24/Siglec-10 pathway. He discusses the technical and ...

Based on MRI scans from 732 prostate cancer patients, the AI model identified the edges of 85 percent of the most radiologically aggressive lesions. Researchers at Mass General Brigham have trained ...

article Harnessing the CD24/Siglec-10 pathway: immunotherapy innovation 17 October 2024 | By Dr Yang Liu (OncoC4) Renowned immunologist Dr Yang Liu shares his insights into the preclinical studies ...